Core Insights - Galectin Therapeutics, Inc. reported significant advancements in the belapectin development program, particularly in addressing MASH cirrhosis and portal hypertension, with promising data from the NAVIGATE dataset [2][3] Financial Highlights - The company secured a $10 million line of credit, extending its cash runway through April 2027 [3] - As of December 31, 2025, Galectin had $17.7 million in unrestricted cash and cash equivalents, alongside the $10 million line of credit [10] - Research and development expenses decreased to $14.3 million in 2025 from $36.6 million in 2024, primarily due to the conclusion of the NAVIGATE trial [10] - The net loss applicable to common stockholders for 2025 was $31.0 million, or ($0.48) per share, down from a net loss of $47.2 million, or ($0.76) per share, in 2024 [10][13] Belapectin Program Highlights - Belapectin targets galectin-3, a protein involved in fibrosis and inflammation related to MASH and portal hypertension [4] - The NAVIGATE Phase 2b/3 trial showed a 43.2% reduction in varices incidence at 18 months in the intent-to-treat population and a 49.3% reduction in the per-protocol population [5] - In U.S. patients within the per-protocol population, belapectin 2 mg/kg reduced varices incidence by 68.1% compared to placebo [5] - Safety results indicated no drug-related serious adverse events, with similar rates of treatment-emergent adverse events across groups [5] Biomarker Insights - Additional analyses from the NAVIGATE trial demonstrated consistent signals across non-invasive markers of fibrosis and liver stiffness, supporting belapectin's antifibrotic activity [6][10] - The company plans to present new analyses at the EASL Congress in May 2026, including findings on reduced varices and risk reduction in portal hypertension [10]

Core Viewpoint - Galectin Therapeutics reported positive clinical data for belapectin, indicating its potential to slow disease progression in patients with compensated MASH cirrhosis, and submitted the NAVIGATE data package to the FDA for feedback on next steps [2][4]. Clinical Data Summary - The NAVIGATE trial presented at AASLD showed consistent improvements in key biomarkers, including FibroScan, ELF, and PRO-C3, supporting belapectin's antifibrotic activity [2][4]. - Belapectin demonstrated a significant reduction in clinically significant portal hypertension (CSPH) risk categories, with a decrease from 33.3% to 25.9% in the 2 mg/kg group, compared to a smaller decrease from 34.2% to 32.9% in the placebo group [8]. - The treatment also improved the no/low-risk category for CSPH, increasing from 42.0% to 56.8% in the belapectin group versus an increase from 44.7% to 51.3% in the placebo group [8]. Financial Highlights - As of September 30, 2025, the company reported cash and cash equivalents of $11.5 million, with total assets of $12.9 million [14]. - Research and development expenses for Q3 2025 were $2.6 million, a decrease from $7.6 million in Q3 2024, primarily due to the timing of expenditures related to the NAVIGATE trial [6][12]. - The net loss applicable to common stockholders for Q3 2025 was $8.2 million, or ($0.13) per share, compared to a net loss of $11.2 million, or ($0.18) per share in Q3 2024 [12][13].